Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Abstract BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a...

詳細記述

保存先:
書誌詳細
主要な著者: Elio Novembre (著者), Mariangela Tosca (著者), Carlo Caffarelli (著者), Mauro Calvani (著者), Fabio Cardinale (著者), Riccardo Castagnoli (著者), Elena Chiappini (著者), Claudio Cravidi (著者), Michele Miraglia Del Giudice (著者), Marzia Duse (著者), Amelia Licari (著者), Sara Manti (著者), Alberto Martelli (著者), Giampaolo Ricci (著者), Giuseppe Pingitore (著者), Gian Luigi Marseglia (著者)
フォーマット: 図書
出版事項: BMC, 2022-05-01T00:00:00Z.
主題:
オンライン・アクセス:Connect to this object online.
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料